This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Two-Year Data Show Long-Term Benefits Of Chronic Soliris® Therapy In Patients With AHUS

Soliris in aHUS Patients with Progressing TMA Despite Intensive PE/PI

In an oral presentation today, researchers presented two-year follow-up data from a prospective, open-label, single-arm phase 2 study in 17 adult and adolescent patients with aHUS who had presented with progressive clinical TMA complications despite intensive plasma exchange or plasma infusion (PE/PI). Patients had been diagnosed with aHUS for a median of 10 months before the start of the study, and 71% had severe renal impairment, with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m 2 at baseline. Seventeen patients were enrolled in the initial study and received Soliris for 26 weeks. Thirteen of the 17 patients continued into a long-term extension phase. Patients were evaluated for a median duration of 100 weeks. Data for all 17 patients were analyzed using repeated measures models and response through data cutoff for each patient. 1

The study achieved its primary endpoint, as mean platelet count improved from baseline at 26 weeks (p=0.0001). Additionally, the improved platelet count continued over two years (p<0.001), indicating sustained inhibition of complement-mediated TMA with ongoing eculizumab treatment. Platelet normalization (≥150x10 9/L) was achieved in 13 of 15 patients (87%) who had low platelets at baseline by 26 weeks and was maintained through two years for 12 of the 13 patients. TMA event-free status (at least 12 consecutive weeks of stable platelet count, no PE/PI, and no new dialysis) was also achieved rapidly and maintained through two years. Specifically, 15 of 17 (88%) Soliris-treated patients achieved TMA event-free status through each data cut-off point (26 weeks, one year, and two years), and TMA event-free status was achieved regardless of the identification of a genetic complement mutation. Hematologic normalization also improved with chronic Soliris treatment over two years: 13 of 17 (76%) Soliris-treated patients achieved and maintained hematologic normalization through 26 weeks, and 15 of 17 (88%) Soliris-treated patients achieved and maintained hematologic normalization through one year and two years. 1

Investigators also observed that chronic Soliris treatment was associated with a sustained improvement in eGFR with a mean change from baseline of 32.0 mL/min/1.73m 2 through 26 weeks (p=0.001) and 35.2 mL/min/1.73m 2 through two years (p=0.0005). Improvement in eGFR was rapid over the first 4 weeks (positive rate of change p<0.0001), and continued to improve with further Soliris treatment from week 4 through two years (p=0.03). Chronic kidney disease (CKD) improvement of at least one stage was reported in 10 patients (59%) at 26 weeks and in 12 patients (71%) at two years. A serum creatinine improvement of at least 25% was observed in 11 patients (65%) at 26 weeks and in 13 patients (76%) at two years. Soliris treatment also eliminated the need for dialysis in four of five patients receiving dialysis at baseline. The researchers also observed that earlier intervention with Soliris was associated with greater increases in eGFR (p<0.01). In addition, Soliris significantly improved quality of life over two years (p<0.0001). 1

“The two-year data show that longer Soliris treatment led to continued improvements and better outcomes for patients with aHUS, including sustained inhibition of complement-mediated TMA, a reduced burden of TMA interventions, and markedly improved renal function,” said Christophe Legendre, M.D., Professor of Nephrology at the University of Paris Descartes and Hôpital Necker in Paris, France, who presented the data at ASN. “Moreover, earlier treatment was associated with better renal outcomes. No deaths were reported during the two-year study, providing further evidence of the long-term benefits of Soliris in this devastating and life-threatening disease.”

2 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs